Presently unknown is whether and to what extent CV-RM is translated into clinical practice. In a retrospective cohort -comprising 251 patients with RA, 251 patients with diabetes, and 251 general population individuals -Desai and colleagues therefore investigated the identifi cation and management of CRFs by rheumatologists and primary care physicians (PCPs) [1] . RA patients had to be registered at the University of Michigan Health System for at least 12 months between June 2007 and April 2012 and had been evaluated both by their rheumatologist as well as the PCP. CRFs of interest were smoking, exercise, weight, blood pressure, lipid profi le, and fasting blood glucose.
In RA, PCPs identifi ed and managed most CRFs more frequently than rheumatologists. Secondly, identifi cation of CRFs by rheumatologists in RA patients with elevated C-reactive protein levels was not diff erent as compared with those with normal C-reactive protein levels. A third important obser vation was that PCPs identifi ed and managed CRFs more frequently in patients with diabetes, followed by general population individuals and least often in RA patients. Th ese striking results raise several issues.
First, it is hard to believe that the largely absent CV-RM by rheumatologists is explained by under-recognition because the increased CV risk in RA must presently be well known among rheumatologists. A large amount of literature on this topic has been published over the last decade. Additionally, the necessity to screen, identify, and manage CRFs is incorporated into training programmes for rheumatology residents [2] . Against this background, it is important to realise that there is a lag time between the publication of the EULAR guideline and its actual implementation (that is, the guideline was published in 2010 [3] while the current study started in 2007). In other words, CV-RM in today's clinical practice might have been improved, but not yet recognised.
Second, that the CV risk in RA is related to the infl ammatory burden is well known. Nevertheless, the present study did not indicate that there is more attention for CV-RM by rheumatologists in patients with a higher infl ammatory load.
Abstract
Rheumatoid arthritis (RA) is associated with a similar cardiovascular risk to that in diabetes, and therefore cardiovascular risk management (CV-RM) -that is, identifi cation and treatment of cardiovascular risk factors (CRFs) -is mandatory. However, whether and to what extent this is done in daily clinical practice is unknown. In a retrospective cohort investigation, CV-RM was therefore compared between rheumatologists and primary care physicians (PCPs). Remarkably, CRFs in RA were less frequently identifi ed and managed by rheumatologists in comparison with PCPs. In addition, PCPs assessed CRFs less frequently in RA than in diabetes. Obviously, there is a clear need for improvement of CV-RM in RA and this should be a joint eff ort from the rheumatologist and the PCP.
Th ird, undertreatment of the increased CV risk in RA by PCPs might be explained by under-recognition because CRFs were assessed more frequently in diabetes in comparison with RA.
Th e EULAR guidelines recommend screening and identifi cation of CRFs in all RA patients, and, if indicated according to CV risk-prediction charts, adequate management. As accurate assessment of CV risk depends on RA characteristics, the EULAR favoured individualising risk assessment. Hence, a risk multiplication factor of 1.5 should be used in the presence of two of the following criteria: disease duration >10 years, rheumatoid factor, and/or anti-cyclic citrullinated peptide positivity or the presence of extra-articular manifestations. However, alternative approaches have been suggested -for example, increasing the age of an RA patient by 10 years to obtain a more precise CV risk estimate or to use other risk scores. Perhaps this lack of an RA-specifi c CV riskprediction model hampers CV-RM implementation. Obviously, this discussion can only be solved by developing a RA-specifi c CV risk-prediction model, but this will take several years to complete.
One may obviously argue that, due to its retrospective design, the strength of the conclusions of Desai and colleagues may be limited; however, they are in line with other recently published literature and thus confi rm extending evidence that CV-RM is poorly conducted in RA, both by rheumatologists and PCPs. Another argument against CV-RM in RA is that we should wait until trials have been conducted that demonstrate the effi cacy of statins and antihypertensive agents in RA. However, it will be (many) years before specifi c risk models are available and withholding cardiopreventive drugs that are very likely to work also in our high-risk population is unethical. More over, it is important to realise that, due to the decreased incidence of CV events in the last decades, CV preven tion trials are nowadays very diffi cult to conduct. For instance, the TRACE-RA study [4] -a large placebo-controlled double-blind primary CV prevention trial in RA with atorvastatinwas stopped prematurely owing to the very low number of CV events that occurred.
Altogether, the study from Desai and colleagues provides three important clues for improvement of CV-RM in RA. First, more education is urgently needed for both rheumatologists and PCPs. Second, it is important to realise that the contribution of higher prevalence CRFs in RA is one side of the coin, but the other side is eff ective suppression of the infl ammation. Th e latter is a clear task for the rheumatologist. Th ird, CV care of a RA patient should be a joint eff ort by the rheumatologist and the PCP, and they should collaborate and agree on who performs the screening, identifi cation, and, if required, management of CRFs.
